CClinicalTrials.gg
Sign In
CompletedNCT03948451Updated Jul 15, 2019

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in Volunteers

A Phase 1 interventional study of [14C]AZD5718 Oral Suspension in Cardiovascular Disease, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-15.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

The Sponsor is developing the test medicine, AZD5718, for the potential treatment of cardiovascular disease.

The study is an open-label, single dose study involving 6 healthy male subjects. The volunteers will receive a single dose of 200 mg radiolabelled AZD5718 (14C-AZD5718 Oral Suspension) containing not more than 9.9 MBq of radiocarbon.

Volunteers will attend the clinic for 9 days (Day -1 to Day 8) to receive a single dose of the test medicine. It is planned that the volunteers will be discharged as a group once all volunteers have reached the discharge criteria. This may result in the subjects being discharged as a group prior to completion of the planned residency period. If the discharge criteria are not met by volunteers by Day 8, the individual volunteers who have not met the criteria will remain in the clinical unit for a further 48 h (until Day 10).

A follow-up call will take place 7 to 10 days after discharge to ensure the ongoing wellbeing of volunteers.

02

Conditions studied

  • Cardiovascular Disease

Keywords

  • Coronary Artery Disease
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 6 is below the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.

Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Provision of signed and dated, written informed consent prior to any study specific procedures.
  2. Healthy male subjects aged 30 to 65 years with suitable veins for cannulation or repeated venepuncture.
  3. Have a body mass index of 18.5 to 35.0 kg/m2, and weigh at least 50 kg and no more than 100 kg, as measured at screening.
  4. Must have regular bowel movements (ie, average stool production of ≥1 and ≤3 stools per day).
  5. Must be willing and able to communicate and participate in the whole study.
  6. Must be surgically sterile or agree to adhere to the contraception requirements.

Exclusion criteria

Exclusion Criteria:

  1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results of the volunteer's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  4. Subjects with Gilbert's syndrome or subjects with a history of cholecystectomy or gall stones.
  5. Any confirmed clinically significant abnormalities in clinical chemistry, haematology or urinalysis as judged by the investigator.
  6. Any confirmed clinically significant abnormal findings in vital signs, as judged by the investigator.
  7. Any confirmed clinically significant abnormal findings in 12-lead ECG, as judged by the investigator.
  8. Any positive result at screening for serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results.
  9. Known or suspected history of drug or alcohol abuse within the past 2 years, as judged by the investigator.
  10. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 90 days of the first administration of IMP in this study. The period of exclusion ends 90 days after the final dose. Note: subjects consented and screened, but not enrolled in this study or a previous Phase I study are not excluded.
  11. Plasma donation within 1 month of screening or any blood donation/loss of more than 500 mL of blood during the 3 months prior to screening.
  12. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5718 or the formulation excipients. Hay fever is allowed unless it is active.
  13. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening and admission.
  14. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months.
  15. Confirmed positive screen for drugs of abuse at screening or admission to the clinical unit or positive screen for alcohol at screening or admission to the clinical unit.
  16. Herbal preparations/medications are not allowed throughout the study. These herbal medications include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng. Subjects should stop using these herbal medications 14 days prior to administration of [14C]AZD5718.
  17. Use of any prescribed or nonprescribed medication including antacids, H2 antagonists, PPI, analgesics (other than paracetamol/acetaminophen up to 4 g/day), vitamins and minerals during the 14 days prior to administration of [14C]AZD5718 or longer if the medication has a longer half-life (see Section 11.4). Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.
  18. Known or suspected history of alcohol or drug abuse or regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type).
  19. Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
  20. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
  21. Judgment by the investigator that the volunteer should not participate in the study if they have any ongoing or recent (ie during the screening period) minor medical complaints that may interfere with the interpretation of the study data or are considered unlikely to comply with the study procedures, restrictions and requirements.
  22. Failure to satisfy the investigator of fitness to participate for any other reason.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]AZD5718 Oral Suspension

    One 200 mg dose of \[14C\]AZD5718 Oral Suspension

    Drug: [14C]AZD5718 Oral Suspension

Interventions

  • Drug[14C]AZD5718 Oral Suspension

    200 mg dose of \[14C\]AZD5718 Oral Suspension

    Also known as: [14C]AZD5718

06

What researchers measure

Primary outcomes

  1. The amount of AZD5718 excreted (Ae)

    Assessment of the total radioactivity by measuring the amount of AZD5718 excreted (Ae)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  2. Amount of AZD5718 excreted and expressed as a percentage of the administered dose (Fe)

    Assessment of the total radioactivity by measuring the amount of AZD5718 excreted and expressed as a percentage of the administered dose (Fe)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  3. The cumulative amount of AZD5718 excreted (CumAe)

    Assessment of the total radioactivity by measuring the cumulative amount of AZD5718 excreted (CumAe)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  4. The cumulative amount of AZD5718 excreted and expressed as a percentage of the administered dose (CumFe)

    Assessment of the total radioactivity by measuring the cumulative amount of AZD5718 excreted and expressed as a percentage of the administered dose (CumFe)

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  5. Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites and structural identification by assessing liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  6. Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites and structural identification by assessing liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Collection of urine samples from pre-dose until 168 hours post-dose

  7. Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites and structural identification by assessing liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Collection of faecal samples from pre-dose until 168 hours post-dose

  8. Time to maximum concentration (tmax) for AZD5718 and total radioactivity

    Assessment of AZD5718 and total radioactivity by measuring the time to maximum concentration (tmax)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  9. Maximum plasma concentration (cmax) for AZD5718 and total radioactivity

    Assessment of AZD5718 and total radioactivity by measuring the maximum plasma concentration (cmax)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  10. Area under the concentration time curve to the last quantifiable concentration (AUC last) for AZD5718 and total radioactivity

    Assessment of AZD5718 and total radioactivity by measuring the concentration time curve to the last quantifiable concentration (AUC last)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  11. Area under the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf) for AZD5718 and total radioactivity

    Assessment of AZD5718 and total radioactivity by measuring the concentration time curve from time zero to the last quantifiable concentration (AUC0-inf)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  12. Apparent terminal Elimination Half-life (t1/2,λz) for AZD5718 and total radioactivity

    Assessment of AZD5718 and total radioactivity by measuring the Elimination Half-life (t1/2,λz)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  13. Oral clearance (CL/F) of AZD5718

    Assessment of the oral clearance of AZD5718 by measuring the apparent oral clearance (CL/F)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  14. Apparent Volume of Distribution (Vz/F) of AZD5718

    Assessment of the oral PK (pharmacokinetics) of AZD5718by measuring the Apparent Volume of Distribution (Vz/F)

    Time frame: Collection of plasma samples from pre-dose until 168 hours post-dose

  15. The amount of AZD5718 excreted (Ae)

    Assessment of the oral PK (pharmacokinetics) of AZD5718 by measuring the amount of AZD5718 excreted (Ae)

    Time frame: Collection of urine and faecal samples from pre-dose until 168 hours post-dose

  16. Amount of AZD5718 excreted and expressed as a percentage of the administered dose (Fe)

    Assessment of the oral PK (pharmacokinetics) of AZD5718 by measuring the amount of AZD5718 excreted and expressed as a percentage of the administered dose (Fe)

    Time frame: Collection of urine and faecal samples from pre-dose until 168 hours post-dose

  17. Renal clearance (Clr) in urine of AZD5718

    Assessment of the oral PK (pharmacokinetics) by measuring the renal clearance (Clr)

    Time frame: Collection of urine samples from pre-dose until 168 hours post-dose

Secondary outcomes

  1. Evaluation of whole blood:plasma concentration ratios for total radioactivity

    Assessment of total radioactivity in whole blood and plasma

    Time frame: Blood samples collected until 168 hours post-dose

  2. Number of adverse events (AE) experienced by subjects

    Safety and tolerability assessed through incidence of AE

    Time frame: AEs recorded from the time of informed consent until discharge from the study (168 hours post-dose)

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03948451
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
May 14, 2019
Start date
Apr 30, 2019
Primary completion
Jul 2, 2019
Completion
Jul 2, 2019
Last update
Jul 15, 2019

Study contacts

Sharan Sidhu, MBChB, BAO, MRCS, MFPM
principal investigator · Quotient Sciences Limited (indemnified by Medical Protection Society)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cardiovascular Diseases→

Other studies from this sponsor

AstraZeneca

Start the discussion